Charles River has validated a model of chronic pulmonary fibrosis. Instillation of bleomycin into the lungs results in acute inflammation followed by a more chronic fibrotic response. Treatment can be initiated at earlier or later time points to assess the effects of candidate agents on either aspect of this model. LPS instillation can be used as a model of the inflammatory response to infectious agents. Histologic, biochemical and cellular end points are used to monitor efficacy. Additionally, the use of activatable fluorescence probes permits the in vivo assessment of the activity of relevant proteases, such as cathepsins, elastase and MMPs.
For more information about our Bleomycin-Induced Pulmonary Fibrosis model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.